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Objective: To assess a mitochondrion-related phenotype in patients with osteoarthri-
tis (OA). Methods: Serum levels of the following OA-related biomarkers: matrix
metalloproteinase-1 (MMP-1); MMP-3; MMP-13; myeloperoxidase (MPO); a peptide of
the alpha-helical region of type II collagen, Coll2-1, and its nitrated form Coll2-1NO2;a
C-terminal neoepitope generated by the collagenase-mediated cleavage of collagen type
II triple helix, C2C; the C-propeptide of collagen type II, CPII; hyaluronic acid (HA); human
cartilage glycoprotein 39,YKL -40; cartilage oligomeric matrix protein; and cathepsin K were
analyzed in 48 OA patients and 52 healthy controls carrying the haplogroups H and J.
Logistic regression models and receiver operating characteristic (ROC) curves were per-
formed to predict the onset of OA. Results: MMP-13 was the only biomarker signiﬁcantly
increased in OA patients compared to healthy controls in both haplogroups H and J. The
collagen type II biomarkers, Coll2-1, Coll2-1NO2, the Coll2-1NO2/Coll2-1 ratio, C2C, CPII,
and the C2C:CPII ratio were signiﬁcantly increased in OA patients carrying haplogroup H
compared to OA carriers of the haplogroup J.Two logistic regression models for diagnosis
were constructed and adjusted for age, gender, and body mass index. For haplogroup H,
the biomarkers signiﬁcantly associated with OA were MMP-13 and Coll2-1; the area under
the curve (AUC) of the ROC curve for this model was 0.952 (95% CI=0.892–1.012). For
haplogroup J, the only biomarker signiﬁcantly associated with OA was MMP-13; the AUC
forthismodelwas0.895(95%CI=0.801–0.989). Conclusion:ThemitochondrialDNAhap-
logroups are potential complementary candidates for biomarkers of OA; their genotyping in
conjunction with the assessment of classical protein molecular markers is recommended.
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INTRODUCTION
Osteoarthritis (OA), the most common form of joint disease and
cause of musculoskeletal disability in elderly people, is a disease
affecting articular cartilage, bone, and soft tissue leading to joint
destructionandsevereimpairmentofmobility(FelsonandZhang,
1998). It is the main cause of work incapacity and one of the most
common reasons for visiting primary care physicians. Among the
risk factors that play a role in OA, gender, age, behavioral inﬂu-
ences, obesity, estrogen loss in women and genetic contribution,
are notable (Felson and Zhang, 1998;Valdes et al.,2004).
OA is traditionally associated with radiographic signs of joint
space narrowing, osteophyte formation, and subchondral sclero-
sis.Currently,thediagnosisof OAreliesonthedescriptionof pain
symptoms, stiffness in the affected joints and the use of radiogra-
phy as the reference technique for determining the grade of joint
destruction. However, radiographic signs and clinical symptoms
only develop in late-stage OA when signiﬁcant joint damage has
alreadyoccurred(Cibereetal.,2009).Currenttreatmentstrategies
are limited, being mainly based on analgesia and, in some cases,
surgical procedures (Spil van et al.,2010).
Because OA affects mainly bone, cartilage, and the synovium,
structural molecules derived from these tissues could be candi-
datebiologicalmarkersforOA.Biomarkersaremoleculesreleased
into biological ﬂuids during the process of tissue biosynthesis
and turnover. The target of the use of biomarkers is to detect
changes arising from OA with more reliability, sensitivity, and
preferably at an earlier stage of the disease (Garnero et al., 2001,
2002).
With this in mind, several groups have studied potential bio-
markers for OA, with sufﬁciently controversial results that some
authors express some limitations about their use as molecular
markers for OA (Felson and Lohmander, 2009). Our group pro-
poses new candidate genetic biomarkers, the mitochondrial DNA
(mtDNA)haplogroups,whichwesuggestcanbeusefulascomple-
mentary factors when the classical OA-related molecular markers
are analyzed.
The mtDNA haplogroups have been associated with several
multifactorial diseases, including Alzheimer’s (van der Walt et al.,
2003), Parkinson’s (van der Walt et al., 2004), or Leber hereditary
optic neuropathy (LHON; Torroni et al., 1997). Interestingly, we
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detectedalowerriskfordevelopingkneeandhipOAincarriersof
the mtDNA haplogroup J in a Spanish population (Rego-Pérez
et al., 2008; Rego et al., 2010) and reported that some of the
mtDNA haplogroups are associated with changes in serum lev-
els of several classical OA-related molecular markers (Rego-Pérez
et al., 2010, 2011). The proposed mechanism relies on the dif-
ferent metabolic characteristics of these haplogroups,reﬂected by
the performance of the mitochondrial oxidative phosphorylation
system (OXPHOS) of each haplogroup (Ruiz-Pesini et al., 2000;
Gómez-Durán et al.,2010).
These ﬁndings and others strengthen the role of mitochon-
dria in the pathogenesis of OA. A signiﬁcant decrease in com-
plex II and III activity in OA chondrocytes compared with
normal chondrocytes has been demonstrated, and mitochondr-
ial mass was also shown to be increased in OA chondrocytes
(Maneiro et al., 2003). The apoptotic mitochondrial pathway
has been implicated as one of the major cellular pathways of
apoptosis in OA chondrocytes (Kim and Blanco, 2007). In addi-
tion, the inhibition of complexes III and V of the mitochon-
drial respiratory chain (MRC) causes an increased inﬂamma-
tory response, which is potentially relevant to the production
of prostaglandin E2 (PGE2) and reactive oxygen species (ROS;
Cillero-Pastor et al.,2008). Mitochondrial free radical production
has been shown to compromise chondrocyte function (Blanco
et al., 2004; Henrotin and Kurz, 2007), causing mtDNA dam-
age and reduced mtDNA capacity for repair (Grishko et al.,
2009).
This study aims to assess a mitochondrion-related phenotype
in OA patients. Logistic regression models that include the analy-
ses of different OA-related biomarkers, mtDNA haplogroups and
other clinical variables OA-related, such as gender, age, and body
massindex(BMI)wereperformedinapopulationfromNorthern
Spain.
MATERIALS AND METHODS
SUBJECTS
The population analyzed in this study has been previously
described(Rego-Pérezetal.,2010).Atotalof 48unrelatedpatients
diagnosed with knee or hip OA were included in the present
study, 25 carrying haplogroup J and 23 carrying haplogroup H.
Patients meeting the inclusion criteria for this study included
32 females and 16 males older than 41years-old (mean age:
68.48±7.64years-old;range:52–95),and diagnosed with OA fol-
lowing the American College of Rheumatology (ACR) criteria
(Altman et al., 1986). Of the 52 subjects who met the inclusion
criteria for normal subjects, 25 carried haplogroup J and 27 hap-
logroup H. These control subjects included 27 females and 25
males older than 41years-old (mean age: 66.5±11.25years-old;
range: 42–91), who did not meet the ACR criteria for knee or hip
OA. Knee and hip radiographs from all 100 subjects were classi-
ﬁed according to the Kellgren and Lawrence (K/L) scoring system,
which ranges from Grade 0 to Grade IV (Kellgren and Lawrence,
1957). The clinical variables gender, age, and BMI were collected
forallsubjects.Inallcases,informedconsentandtheagreementof
the ethical committee from Galician Health Administration were
obtained.
mtDNA HAPLOGROUPS GENOTYPING
The samples obtained for the study were haplogroup-typed using
a previously described assay (Rego-Pérez et al., 2008). For this
study, only subjects carrying mtDNA haplogroups H and J were
included.
MOLECULAR BIOMARKERS
Fasting blood samples were collected from each subject in plain
tubes containing separation gel. These were allowed to stand for
20min, then centrifuged for 10min at 800×g. The serum was
then divided into aliquots and stored at −80˚C pending assay.
For this study the following 12 OA-related molecular mark-
ers were measured: metalloproteinase-1 (MMP-1; interstitial col-
lagenase, pro-enzyme), MMP-3 (stromelysin 1, active enzyme),
MMP-13(collagenase3,activeenzyme),myeloperoxidase(MPO),
a denaturation epitope of the triple helical domain of collagen
typeII(Coll2-1)anditsnitratedform(Coll2-1NO2),aC-terminal
neoepitopegeneratedbythecollagenase-mediatedcleavageof col-
lagentypeIItriplehelix(C2C),theprocollagentypeIIC-terminal
propeptide (CPII), hyaluronic acid (HA), cartilage glycoprotein
39 (YKL-40), cartilage oligomeric matrix protein (COMP), and
cathepsin K,a cysteine protease that also cleaves the triple helix of
collagen type II. The determination of MPO, Coll2-1, and Coll2-
1NO2 was performed at the Bone and Cartilage Research Unit of
the University of Liege (Belgium), using a previously described
assay (Deberg et al., 2008). The remaining biomarkers were mea-
sured in our laboratory using enzyme-linked immunosorbent
assays (ELISAs) according to the manufacturer’s recommenda-
tions. Serum MMP-1 and MMP-3 levels were measured using
kits from R&D Systems (Minneapolis, MN, USA), MMP-13 was
measured using a kit from Bender MedSystems (Vienna,Austria),
C2C, and CPII were measured using kits from Ibex Technolo-
gies (Montreal, QC, Canada), HA was measured using a kit from
Corgenix Medical Corporation (Denver, CO, USA), YKL-40 was
measured using a kit from Quidel Corporation (San Diego, CA,
USA),COMP was measured using a kit fromAbnova (Taipei City,
Taiwan)andcathepsinKwasmeasuredusingakitfromBiomedica
Medizinprodukte (GmbH & Co KGVienna,Austria).
The Coll2-1NO2/Coll2-1 ratio was utilized as an additional
measure of oxidative stress-mediated cartilage degradation, and
the C2C/CPII ratio as a further index of cartilage breakdown.
Thedeterminationoftheserumlevelsofallthebiomarkersana-
lyzed in this study was performed by simultaneously assaying OA
patients and healthy controls regardless of mtDNA haplogroup.
STATISTICAL ANALYSIS
StatisticalanalyseswereperformedusingSPSSsoftware,release17
(Chicago, IL, USA), and EPIDAT 3.1 (Dirección Xeral de Saúde
Pública. Consellería de Sanidade. Xunta de Galicia. Santiago de
Compostela, España). Haplogroups H and J were analyzed sep-
arately. A univariate analysis was performed on each of these
haplogroups to compare serum levels of the biomarkers between
OApatientsandhealthycontrolsusingtheMann–WhitneyU-test.
Receiver operating characteristic (ROC) curves were used to
analyze the ability of different molecular markers to discriminate
between OA patients and healthy controls in haplogroups H and
J.Theareaunderthecurve(AUC)andits95%conﬁdenceinterval
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were calculated, and only those curves with an AUC≥0.8 were
considered as discriminative. The ROC curves for each of the
biomarkers were compared using the method of DeLong et al.
(1988).
Multiplelogisticregressionmodelsadjustedforage,gender,and
BMI were used for each haplogroup studied to determine which
biomarkersaresigniﬁcantlyassociatedwithOApatients(diagnos-
ticmodel).Aforwardstepwiseapproachwasfollowedtoconstruct
the ﬁnal models. The optimal probability cut-off was assessed
by maximizing the Youden index (sensitivity+speciﬁcity-1). For
this cut-off, sensitivity, speciﬁcity, and positive likelihood ratio
(LR) values were also calculated. The ROC curves resulting from
the regression models were developed taking into account only
signiﬁcant variables.
RESULTS
Atotalcohortof 100subjects,48OApatients,and52healthycon-
trols, were included in this study; 50 were carriers of haplogroup
H and 50 of haplogroup J.
UNIVARIATE ANALYSIS FOR COMPARISON OF THE TESTED
MOLECULAR MARKERS
The mean values for the different molecular markers in each hap-
logroup, comparing OA patients and healthy controls with their
corresponding p-values, are shown in Table 1. The results show
thatonlyMMP-13issigniﬁcantlyincreasedinOApatientsineither
haplogroup. Most of the catabolic markers are increased in OA
patients who carry haplogroup H, even when compared to OA
patients that carry haplogroup J (Table 1; Figure1). Interestingly,
healthy controls carrying haplogroup J show signiﬁcantly higher
levels of MMP-3 and C2C than OA patients with this haplogroup.
In summary,these results clearly show a different proﬁle for some
of the biomarkers in these two haplogroups.
ROC CURVES FOR THE DIAGNOSIS OF THE MOLECULAR MARKERS
The ROC curves and their corresponding AUC values for all
the biomarkers were calculated. ROC curves were performed for
each biomarker in each haplogroup. For carriers of haplogroup
H, the most discriminative biomarkers were MMP-13, AUC
value 0.869 (95% CI=0.758–0.979), Coll2-1NO2, 0.863 (95%
CI=0.756–0.970),Colll2-1NO2/Coll2-1,0.836(95%CI=0.719–
0.953), C2C:CPII, 0.831 (95% CI=0.718–0.944), and HA, 0.841
(95% CI=0.727–0.955; Table 2). Carriers of haplogroup J had
only the MMP-13 biomarker, with an AUC of 0.867 (95%
CI=0.749–0.985), able to discriminate between OA patients and
healthy controls (Table 2).
Because MMP-13 was the most consistent biomarker in all
the analyses, a comparison of the ROC curve for MMP-13 and
the ROC curves for each of the other biomarkers was per-
formed. For carriers of haplogroup H, the AUC of MMP-13
was statistically different from those of MMP-1 (p =0.0008),
C2C(p =0.0004),YKL-40(p =0.0017),andCOMP(p =0.0040).
For carriers of haplogroup J, the AUC of MMP-13 was statis-
tically different from MMP-1 (p =0.0005), MPO (p =0.0104),
Colll2-1NO2/Coll2-1 (p =0.0039), C2C:CPII (p =0.0081), HA
(p =0.0049), and COMP (p =0.0015; Table 2).
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS FOR DIAGNOSIS
OF OA
A model to discriminate between OA patients and healthy con-
trols was developed for each of the two haplogroups to include
the clinical variables gender, age, and BMI as well as the tested
biomarkers.
Afteradjustingforage,gender,andBMI,haplogroupHcarriers
hadbiomarkersMMP-13andColl2-1signiﬁcantlyassociatedwith
OA (Table 3).TheAUCforthismodelwas0.952(95%CI=0.892–
1.012).Theoptimalprobabilitycut-offfordiscriminationbetween
OA and healthy subjects was 0.536, with a sensitivity of 90%, a
speciﬁcity of 95%, and a positive LR of 18.095; thus, the model
discriminated very well between OA patients and healthy con-
trols (Figure 2A). In summary, OA patients with haplogroup H
showed higher serum levels of both MMP-13 and Coll2-1 than
healthy controls with this haplogroup,as well as an increased BMI
and age, regardless of gender.
After adjusting for age, gender, and BMI, patients carrying
haplogroup J showed that biomarker MMP-13 was signiﬁcantly
associated with OA (Table 3). The AUC for this model was 0.895
(95% CI=0.801–0.989). The optimal probability cut-off for dis-
criminating between OA patients and healthy controls was 0.503,
with a sensitivity of 88%, a speciﬁcity of 86%, and a positive LR
of 6.125 (Figure 2B). In summary, OA patients with haplogroup
J showed higher serum levels of MMP-13 than healthy controls
with this haplogroup, as well as an increased BMI, regardless of
age. This model also showed an increased risk of OA in females
(Table 3).
DISCUSSION
This study was performed to ﬁnd a mitochondrion-related phe-
notype in OA patients using the analysis of 12 OA-related mol-
ecular markers and two additional ratios, C2C:CPII and Coll2-
1NO2/Coll2-1. As described above, the choice of haplogroups H
and J was because of the different relationships that our group
previously found between the haplogroup J and the prevalence
and severity of knee (Rego-Pérez et al., 2008) and hip OA (Rego
et al.,2010),and because of the association of haplogroups H and
J with the serum levels of collagen type II markers (Rego-Pérez
et al.,2010).
In previous studies, some of the molecular markers found to
be increased in OA appeared to show no differences between cases
and controls (Rego-Pérez et al., 2010, 2011). This apparent dis-
crepancy may be accounted for by the fact that the serum levels
of some of these markers between cases and controls differed
depending on the haplogroup carried. In this sense, we found
that serum levels of Coll2-1 were (not statistically) increased in
healthy controls (Rego-Pérez et al., 2010), contrarily to the ﬁnd-
ings of other investigators (Deberg et al., 2008); however, the
serum levels of Coll2-1 were increased in OA patients with hap-
logroup H. Even OA patients that carry this haplogroup had also
signiﬁcantly higher serum levels of Coll2-1NO2 than healthy con-
trols carrying either of the haplogroups H or J, and also higher
than OA patients with haplogroup J (Rego-Pérez et al., 2010).
These results were strengthened by measuring the production of
Nitric oxide (NO) in articular chondrocytes, showing that carri-
ers of the mtDNA haplogroup J have lower production of NO
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Table 1 | Univariate analysis of the biomarkers for haplogroups H and J.
Molecular marker Haplogroup H Haplogroup J
Healthy Mean±SD
(n =23)
OA Mean±SD
(n =27)
p* Healthy Mean±SD
(n =23)
OA Mean±SD
(n =27)
p*
MMP-1 (ng/mL) 5.59±4.25 5.47±3.89 0.915 5.31±4.30 5.13±3.4 0.961
MMP-3 (ng/mL) 18.90±10.79 24.89±19.23 0.170 25.98±13.70 15.98±8.89 0.003**
MMP-13 (ng/mL) 0.56±0.31 0.72±0.15 <0.001** 0.48±0.15 0.65±0.15 <0.001**
MPO (ng/mL) 112.93±85.40 181.49±118.74 0.015 141.17±78.73 134.06±143.09 0.201
Coll2-1 (nM) 143.66±33.14 161.31±25.25 0.122 137 .40±50.05 107 .78±54.90 0.015
Coll2-1NO2 (nM) 0.33±0.10 0.52±0.16 <0.001** 0.34±0.17 0.28±0.26 0.079
Coll2-1NO2/Coll2-1 (nM) 0.23±0.06 0.32±0.07 <0.001** 0.25±0.13 0.25±0.24 0.281
C2C (ng/mL) 129.29±43.52 122.55±37 .76 0.884 72.57±39.97 42.92±30.72 0.006**
CPII (ng/mL) 472.48±249.94 610.60±211.74 0.015 393.06±213.03 275.75±178.57 0.067
C2C:CPII (ng/mL) 0.32±0.14 0.21±0.06 <0.001** 0.25±0.37 0.16±0.04 0.388
HA (ng/mL) 41.00±32.52 86.13±45.71 <0.001** 59.56±39.37 66.48±35.56 0.438
YKL -40 (ng/mL) 110.55±89.62 99.57±73.54 0.793 116.63±103.20 71.00±38.21 0.073
COMP (ng/mL) 992.68±540.79 963.67±266.49 0.490 1040.34±562.51 959.64±484.14 0.808
Cathepsin K (pmol/L) 13.24±22.44 15.31±16.85 0.026 14.14±21.94 14.60±22.53 0.123
SD, Standard deviation.
*Mann–Whitney non-parametric U-test.
**Statistical signiﬁcance declared at p≤0.01 due to multiple comparisons.
FIGURE 1 | Mean serum levels of osteoarthritis (OA)-related molecular
markers in OA patients carrying haplogroup H and OA patients carrying
the haplogroup J. (*p ≤0.01); MMP , matrix metalloproteinase; MPO,
myeloperoxidase; Coll2-1, denaturation epitope of the triple helical domain of
collagen type II and Coll2-1NO2 =its nitrated form; C2C, a C-terminal neoepitope
generated by the collagenase-mediated cleavage of collagen type II triple helix;
CPII, the procollagen type II C-terminal propeptide; HA, hyaluronic acid;YKL -40,
cartilage glycoprotein 39; COMP , cartilage oligomeric matrix protein.
than non-J carriers (Fernández-Moreno et al., 2011). It is known
that OA chondrocytes produce NO (Henrotin et al., 1993; Karan
et al., 2003) and that the effect of NO on chondrocyte survival
is mediated by its effect on the MRC (Maneiro et al., 2005). It is
also known that Coll2-1NO2 is an indicator of the oxidative stress
status of the chondrocyte (Deberg et al.,2008),thereby suggesting
thatchondrocytesof haplogroupJcarriersmayhavelessoxidative
stress.
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Table 2 | Comparative analysis of the receiver operating characteristic (ROC) curves of biomarkers for haplogroups H and J.
Molecular marker Haplogroup H Haplogroup J
AUC 95% CI p* AUC 95% CI p*
MMP-1 (ng/mL) 0.509 0.345–0.673 0.0008** 0.504 0.340–0.961 0.0005**
MMP-3 (ng/mL) 0.614 0.457–0.770 0.0185 0.747# 0.609–0.885 0.2001
MMP-13 (ng/mL) 0.869 0.758–0,979 0.867 0.749–0.985
MPO (ng/mL) 0.705 0.558–0.851 0.0505 0.607# 0.446–0.767 0.0104**
Coll2-1 (nM) 0.628 0.472–0.784 0.0155 0.701# 0.548–0.854 0.0905
Coll2-1NO2 (nM) 0.863 0.756–0.970 0.9465 0.645# 0.484–0.806 0.0279
Coll2-1NO2/Coll2-1 (nM) 0.836 0.719–0.953 0.6711 0.589# 0.425–0.753 0.0039**
C2C (ng/mL) 0.488 0.324–0.651 0.0004** 0.726# 0.579–0.874 0.1258
CPII (ng/mL) 0.700 0.552–0.849 0.0662 0.651# 0.497–0.806 0.0162
C2C:CPII (ng/mL) 0.831# 0.718–0.944 0.0895 0.571# 0.409–0.733 0.0081**
HA (ng/mL) 0.841 0.727–0.955 0.7668 0.564 0.401–0.727 0.0049**
YKL -40 (ng/mL) 0.522 0.359–0,684 0.0017** 0.648# 0.494–0.802 0.0253
COMP (ng/mL) 0.557 0.395–0.719 0.0040** 0.520# 0.357–0.683 0.0015**
Cathepsin K (pmol/L) 0.684 0.535–0.834 0.0443 0.627 0.466–0.788 0.0132
AUC, area under the curve. Values in bold indicate the most discriminative (AUC≥0.8).
CI, conﬁdence interval.
#Lower values of the biomarker are associated with OA in carriers of this haplogroup.
*Test for homogeneity of areas comparing the AUC from the MMP-13 from those of the other molecular markers.
**Statistical signiﬁcance declared at p≤0.01 due to multiple comparisons.
Table 3 | Multivariate logistic regression analysis for diagnosis of
osteoarthritis (OA) in haplogroup H and J carriers.
Variables B OR 95% CI p*
HAPLOGROUP H
Age 0.263 1.301 1.026–1.649 0.030**
BMI 0.647 1.910 1.124–3.244 0.017**
MMP-13 0.430 1.537 1.023–2.310 0.038**
Coll2-1 0.104 1.110 1.013–1.217 0.026**
HAPLOGROUP J
BMI 0.404 1.499 1.062–2.115 0.021**
Gender −1.930 0.145 0.026–0.816 0.028**
MMP-13 0.551 1.735 1.017–2.959 0.043**
B=regression coefﬁcient.
OR, odd ratio.
CI, conﬁdence interval.
*p-Value from the logistic regression model.
**Statistical signiﬁcance declared at p≤0.05.
We believe that the explanation for these discrepant results is
related to mtDNA haplogroups. The frequency of distribution
of haplogroups in our cohort is substantially different from that
observed in typical cohorts, which will follow the distribution of
these haplogroups in the general population: haplogroup H 40–
47%andhaplogroupJ7–12%(Torronietal.,1996;Dahmanyetal.,
2006). The frequency distribution in our cohort was the same for
each haplogroup. We see that the results derived from the analy-
sis of carriers of haplogroup H, the most common haplogroup in
Caucasian populations, are more in line with those obtained by
other authors,and reﬂect the fact that serum levels of most of the
catabolic OA-related biomarkers are increased in haplogroup H
carriers, as shown in Figure 1.
In this study, pursuant to the analyses of the ROC curves and
univariate analysis, MMP-13 was the only molecular marker that
differentiated between OA patients and healthy controls in carri-
ersof bothhaplogroupsHandJ,aspreviouslydescribedbyothers
(Reboul et al., 1996; Rego-Pérez et al., 2011). In this sense, a role
for the mitochondrial dysfunction in the expression of the MMPs
has also been proposed (Cillero-Pastor et al., 2008, 2010).
Other molecular markers that have been proposed for differ-
entiating between OA patients and healthy controls, such as HA
(Elliott et al., 2005; Mazières et al., 2006), appear to be increased
in OA patients, but only signiﬁcantly increased in haplogroup H
carriers with OA. HA has been reported to be increased in OA
patients in some studies and was proposed as a surrogate marker
with predictive value for radiographic progression of OA (Maz-
ières et al., 2006; Filková et al., 2009). Our study shows that this
associationisstrongerinhaplogroupHcarriers(Table 1).Because
the pro-inﬂammatory cytokine interleukin-1 (IL-1) is one of the
main cytokines involved in the mitochondrial dysfunction and in
the OA disease, we speculate that this association could be due to
different effects of the IL-1, which is an important factor in the
synovial production of HA (Nishida et al., 2000), on cells with
different mitochondrial backgrounds.
The regression model of diagnosis for haplogroup H carriers
shows that, together with both the BMI and age, those subjects
with higher serum levels of MMP-13 and Coll2-1 are more likely
to be diagnosed with OA. This model resulted in extraordinary
LR and AUC values, hence discriminating very well between OA
patients and healthy controls. On the other hand, the model for
haplogroup J carriers shows that,together with both the BMI and
gender,subjectswithhigherserumlevelsofMMP-13onlyaremore
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FIGURE 2 | Receiver operating characteristic (ROC) curves derived
from the logistic regression models for haplogroups H and J. (A) ROC
curve from the regression model for diagnosis in haplogroup H carriers; (B)
ROC curve from the regression model for diagnosis in haplogroup J
carriers. (AUC, area under the curve; CI, conﬁdence interval; LR, likelihood
ratio).
likely to be diagnosed as having OA, therefore do not appearing
any other biomarker in this model signiﬁcantly associated to dis-
criminate between OA patients and healthy controls. In summary,
theseﬁndingshighlighttheimportanceofthemitochondrialback-
ground in the OA disease, since Coll2-1 appeared signiﬁcantly
increased in OA patients with the mtDNA haplogroup H, but not
in patients with the haplogroup J, probably by the fact that hap-
logroup H carriers have more active collagen type II metabolism
than haplogroup J carriers do, as proposed in our previous work
(Rego-Pérez et al., 2010). Because mtDNA haplogroups H and
J are clearly biochemically different (Wallace, 1999), the possible
differences in OXPHOS performance between them (Ruiz-Pesini
etal.,2000;Martínez-Redondoetal.,2010)couldexplainthemore
active metabolism in haplogroup H carriers; hence CPII levels in
OA patients with haplogroup H are higher than in healthy con-
trols or OA patients with haplogroup J (Rego-Pérez et al., 2010),
which may represent an attempt to repair OA damaged carti-
lage by increasing the synthesis of collagen type II, as previously
described (Aigner et al., 1992; Lohmander et al., 1996; Nelson
et al., 1998). Similarly, metabolic differences between these two
haplogroups could account for our ﬁnding that most of the cata-
boliccollagentypeIIbiomarkersareincreasedinOApatientswho
carry haplogroup H,when compared with OA patients who carry
haplogroup J.
CONCLUSION
Insummary,theresultsobtainedinthisworkareofspecialinterest
because they strengthen the role of the mitochondrion in the OA
process. Either mtDNA haplogroups or an altered mitochondrial
function could explain some of the controversial results reported
in different studies when analyzing the same biomarkers in differ-
entpopulationsof patients.Aparticularbeneﬁtof thisstudyisthe
notableﬁndingthatpatientsthatcarryhaplogroupHshowhigher
levels of all the catabolic markers of OA than those OA patients
thatcarrythemtDNAhaplogroupJ;twodifferentmitochondrion-
related OA phenotypes were clearly deﬁned. Understanding the
inﬂuenceofthemitochondrialbackgroundwillenableustodetect
biomarkers most related to OA, allowing us to design models for
haplogroup-based diagnoses.
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